ReviewHuman genetics2022
Current challenges and opportunities for pharmacogenomics: perspective of the Industry Pharmacogenomics Working Group (I-PWG).
Review in Human genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- CYP2D6 genotype and associated 5-HTClinical and translational science · 2025Pooled it
- Healthcare professionals' and consumers' knowledge, attitudes, perspectives, and education needs in oncology pharmacogenomics: A systematic review.Clinical and translational science · 2023Pooled it
- A blockchain-based framework to support pharmacogenetic data sharing.The pharmacogenomics journal · 2022Pooled it
- Survey on new technologies and precision medicine to advance healthcare.Journal of community genetics · 2026Article
- Leveraging PCORnet® to Advance Clinical Genetics and the Genomic Learning Health System.Medical care · 2026Article
- Qualitative analysis of pharmacogenetic applications in pediatric clinical trials registered on ClinicalTrials.gov.Frontiers in pharmacology · 2026Article
- Pharmacogenomics of treatment toxicities in pediatric B-Cell ALL: toward safer precision therapy.Frontiers in pharmacology · 2026Review
- Scoping review of enablers and challenges of implementing pharmacogenomics testing in the primary care settings.BMJ open · 2024Article
- Machine learning in oncological pharmacogenomics: advancing personalized chemotherapy.Functional & integrative genomics · 2024Review
- Bridging the gap in precision medicine: TranSYS training programme for next-generation scientists.Frontiers in medicine · 2024Article
- Pharmacogenomics and Big Data in medical oncology: developments and challenges.Therapeutic advances in medical oncology · 2024Review
- Enhancing pharmacogenomic data accessibility and drug safety with large language models: a case study with Llama3.1.Experimental biology and medicine (Maywood, N.J.) · 2024Article
- Measurement of CYP1A2 and CYP3A4 activity by a simplified Geneva cocktail approach in a cohort of free-living individuals: a pilot study.Frontiers in pharmacology · 2024Article
- AWOT and CWOT for genotype and genotype-by-treatment interaction joint analysis in pharmacogenetics GWAS.Bioinformatics (Oxford, England) · 2023Article
- Pharmacogenomics: the low-hanging fruit in the personalized medicine tree.Human genetics · 2022Article
- Drug Design: Where We Are and Future Prospects.Molecules (Basel, Switzerland) · 2021Review
- Pharmacogenomics and rare diseases: optimizing drug development and personalized therapeutics.PharmacogenomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmaceutical companies have increasingly utilized genomic data for the selection of drug targets and the development of precision medicine approaches. Most major pharmaceutical companies routinely collect DNA from clinical trial participants and conduct pharmacogenomic (PGx) studies. However, the implementation of PGx studies during clinical development presents a number of challenges. These challenges include adapting to a constantly changing global regulatory environment, challenges in study design and clinical implementation, and the increasing concerns over patient privacy. Advances in the field of genomics are also providing new opportunities for pharmaceutical companies, including the availability of large genomic databases linked to patient health information, the growing use of polygenic risk scores, and the direct sequencing of clinical trial participants. The Industry Pharmacogenomics Working Group (I-PWG) is an association of pharmaceutical companies actively working in the field of pharmacogenomics. This I-PWG perspective will provide an overview of the steps pharmaceutical companies are taking to address each of these challenges, and the approaches being taken to capitalize on emerging scientific opportunities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.